Safety and efficacy of ravidasvir plus sofosbuvir 12 weeks in noncirrhotic and 24 weeks in cirrhotic patients with hepatitis C virus genotypes 1, 2, 3 and 6: The STORM-C-1 phase II/III trial
2018 ◽
Vol 68
◽
pp. S123-S124
◽
Keyword(s):
Phase Ii
◽
2019 ◽
Vol 34
(9)
◽
pp. 1597-1603
◽
Keyword(s):
2006 ◽
Vol 13
(4)
◽
pp. 222-229
◽
Keyword(s):
Keyword(s):
2016 ◽
Vol 22
(34)
◽
pp. 7824
◽
2020 ◽
Vol 24
(4)
◽
pp. 304-309
◽
Keyword(s):